AbbVie Investors Want Records On Testosterone Marketing

Law360 (February 26, 2019, 8:49 PM EST) -- Two AbbVie shareholders filed a complaint in Delaware Chancery Court on Monday seeking an inspection of the pharmaceutical company’s records to investigate whether it undertook an off-label marketing scheme for its testosterone treatment gel in a way that harmed patients and wronged investors.

In the complaint, investors Gregg Davis and Katherine Kay said they want access to corporate books and records based on their belief that AbbVie Inc. directors may have breached their fiduciary duties based on an alleged illegal marketing scheme that sought to widen the scope of ailments that could be treated by the company’s AndroGel therapy, even though...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS